概览
Meeting | October 6-7
DIA’s Advancing Diversity, Equity, and Inclusion Across Life Sciences R&D Meeting will lead the way in sharing knowledge and fostering coalitions to build greater diversity, equity, and inclusion efforts in the life sciences R&D field.
This program has been developed in collaboration with the Diversity & Inclusion in Life Sciences Community.
Registered attendees will receive access to all session recordings for 2 full months post-conference! This allows you to remain flexible with your schedule and not worry if you need to miss a session. Have a conflict with the dates of the conference? Register anyway and you will receive access to the recordings!
-
Why You Can’t Miss It
- Emphasize approaches and actionable solutions learned from years of investment from the biopharmaceutical and medical device industry
- Navigate challenges and best practices that exist in various phases of the drug development lifecycle
- Inspire interactive and compelling discussions to improve industry accountability and sustainability
- Advance dialogue among industry leaders, clinical research sites, patients, academia, the FDA, and those in public policy
-
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Describe efforts that advance clinical trial diversity for racial and ethnic minorities, women, and rare diseases
- Discuss insights on why changing organizational culture to embrace diversity, equity, and inclusion, is an important component of enabling the success of DEI efforts more broadly across multiple areas of R&D
- Apply learnings on how to set your company up for culture change success
- Identify challenges within protocol development and design and how they can impact DEI
- Describe effective ways to integrate community engagement into your clinical trial
- Identity the many challenges that exist in understanding data from defining it from a race and ethnicity perspective, its real-world application and use, and the importance of equitable data in relation to clinical trial development
- Implement effective patient engagement strategies into your own organizational practices
- Evaluate the challenges that impact diversity recruitment, enrollment, and retention in clinical trials
- Describe methods to increase the diversity of the clinical research talent pipeline
-
Meeting Designed For
- Diversity, Equity, and Inclusion
- Clinical Research Operations
- Medical Affairs and Communication
- Patient Advocacy, Engagement and Outcomes
- Professional Education, Training and Development
- Public Policy and Regulatory Affairs
- R&D Strategic Planning
Featured
Want to learn more about Advancing Diversity, Equity, and Inclusion Across Life Sciences R&D Meeting? You've come to the right site!
项目委员会
-
Tamei Elliott, MS Associate Director, Scientific Programs
DIA, United States -
Richardae Araojo, PharmD, MS Associate Commissioner for Minority Health, Director, Office of Minority Health
FDA, United States -
Dyan Bryson Global Strategic Solutions, Clinical Operations Lead, DEICT
Inspired Health Strategies, United States -
Diana Foster, BSN, PhD, MSN Chief Executive Officer
TOTAL Diversity Clinical Trial Management, United States -
Karen Correa, PhD Vice President, Head of Global Clinical Operations
Takeda, United States -
Kevin Freiert, MBA Owner and Chief Executive Officer
Salem Oaks® Consulting, United States -
Barbara Goodman, MBA President and Chief Executive Officer
Cures Within Reach, United States -
Christine Lee, PharmD, PhD Deputy Director, Office of Minority Health and Health Equity (OMHHE), OC
FDA, United States -
Alissa Goodale, DrMed Regulatory Executive Director
Genentech, A Member of the Roche Group, United States -
Amy Sitnick, MA Vice President, Marketing
Greenphire, United States -
Jacqueline Woodruff, MA Clinical Researcher / Anthropologist
Monmouth University, United States -
Stephanie Young Moss, PharmD, MS Pharmacist, Owner
Integrative Pharmacy Outcomes and Consulting, United States -
Representative Invited DIA, United States
